The present invention provides a pharmaceutical composition, for example a vaccine, which comprises a RIFIN, which is able to bind to a mutated LAIR-1 fragment, which broadly binds to erythrocytes infected with Plasmodium falciparum. Such a RIFIN may be useful in the prevention and/or treatment of malaria.